Last reviewed · How we verify
Perianal NRL001 Gel 3 strengths — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Perianal NRL001 Gel 3 strengths (Perianal NRL001 Gel 3 strengths) — Norgine.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Perianal NRL001 Gel 3 strengths TARGET | Perianal NRL001 Gel 3 strengths | Norgine | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Perianal NRL001 Gel 3 strengths CI watch — RSS
- Perianal NRL001 Gel 3 strengths CI watch — Atom
- Perianal NRL001 Gel 3 strengths CI watch — JSON
- Perianal NRL001 Gel 3 strengths alone — RSS
Cite this brief
Drug Landscape (2026). Perianal NRL001 Gel 3 strengths — Competitive Intelligence Brief. https://druglandscape.com/ci/perianal-nrl001-gel-3-strengths. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab